康諾亞-B股票討論區

CM310的III期註冊性臨床試驗結果顯示出優於安慰劑組的顯著療效，包括溼疹面積和嚴重程度指數的改善，研究者整體評分法評分的提高，以及瘙癢控制和生活質量的改善。這可能對康諾亞-B的股價產生積極影響。

$康諾亞-B(02162.HK)$ Short-term share prices are hard to pin down. I remember that in 19 years, Cinda was over 20 billion for a whole year and broke 100 billion in 20 years. In November last year, Kangfang fell to more than 10 billion yuan and rose back to 30 billion yuan in a month or two. In April this year, Corning & Jerry's was only more than 8 billion yuan at its worst, and broke 20 billion yuan in one or two months. Konoya is now left time, firmly optimistic about the first half of next year to stand at $20 billion.